Guggenheim Capital’s PTC Therapeutics PTCT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.68M | Buy |
32,811
+6,432
| +24% | +$464K | 0.02% | 637 |
|
|
2026
Q1 | $1.8M | Sell |
26,379
-14,859
| -36% | -$1.05M | 0.01% | 737 |
|
|
2025
Q4 | $3.13M | Buy |
41,238
+24,450
| +146% | +$1.78M | 0.02% | 553 |
|
|
2025
Q3 | $1.03M | Sell |
16,788
-1,550
| -8% | -$80.7K | 0.01% | 908 |
|
|
2025
Q2 | $896K | Buy |
18,338
+2,317
| +14% | +$110K | 0.01% | 930 |
|
|
2025
Q1 | $816K | Sell |
16,021
-3,465
| -18% | -$173K | 0.01% | 964 |
|
|
2024
Q4 | $880K | Sell |
19,486
-5,661
| -23% | -$242K | 0.01% | 981 |
|
|
2024
Q3 | $933K | Buy |
25,147
+734
| +3% | +$24.6K | 0.01% | 1141 |
|
|
2024
Q2 | $747K | Sell |
24,413
-5,629
| -19% | -$182K | 0.01% | 1254 |
|
|
2024
Q1 | $874K | Sell |
30,042
-1,577
| -5% | -$44.2K | 0.01% | 1249 |
|
|
2023
Q4 | $871K | Buy |
31,619
+5,285
| +20% | +$121K | 0.01% | 1224 |
|
|
2023
Q3 | $590K | Buy |
26,334
+1,800
| +7% | +$66.9K | 0.01% | 1341 |
|
|
2023
Q2 | $998K | Buy |
24,534
+1,298
| +6% | +$63.5K | 0.01% | 1160 |
|
|
2023
Q1 | $1.13M | Buy |
+23,236
| New | +$1.06M | 0.01% | 1124 |
|
|
2021
Q4 | – | Sell |
-36,280
| Closed | -$1.35M | – | 2200 |
|
|
2021
Q3 | $1.35M | Sell |
36,280
-254
| -0.7% | -$10.4K | 0.01% | 1264 |
|
|
2021
Q2 | $1.54M | Buy |
36,534
+3,017
| +9% | +$129K | 0.01% | 1251 |
|
|
2021
Q1 | $1.59M | Sell |
33,517
-150
| -0.4% | -$8.91K | 0.01% | 1151 |
|
|
2020
Q4 | $2.06M | Sell |
33,667
-10,399
| -24% | -$613K | 0.01% | 953 |
|
|
2020
Q3 | $2.06M | Sell |
44,066
-7,690
| -15% | -$379K | 0.01% | 878 |
|
|
2020
Q2 | $2.63M | Buy |
51,756
+5,421
| +12% | +$266K | 0.02% | 765 |
|
|
2020
Q1 | $2.07M | Sell |
46,335
-9,084
| -16% | -$457K | 0.02% | 776 |
|
|
2019
Q4 | $2.66M | Sell |
55,419
-1,531
| -3% | -$65.1K | 0.02% | 927 |
|
|
2019
Q3 | $1.93M | Buy |
56,950
+53
| +0.1% | +$2.31K | 0.02% | 1034 |
|
|
2019
Q2 | $2.56M | Sell |
56,897
-14,810
| -21% | -$585K | 0.02% | 951 |
|
|
2019
Q1 | $2.7M | Buy |
71,707
+7,405
| +12% | +$249K | 0.02% | 944 |
|
|
2018
Q4 | $2.21M | Buy |
+64,302
| New | +$2.31M | 0.02% | 996 |
|
|
2018
Q2 | – | Sell |
-65,289
| Closed | -$1.77M | – | 2546 |
|
|
2018
Q1 | $1.77M | Sell |
65,289
-21,619
| -25% | -$548K | ﹤0.01% | 1724 |
|
|
2017
Q4 | $1.45M | Buy |
+86,908
| New | +$1.47M | ﹤0.01% | 1874 |
|
|
2016
Q2 | – | Sell |
-166,541
| Closed | -$1.07M | – | 2920 |
|
|
2016
Q1 | $1.07M | Buy |
166,541
+115,384
| +226% | +$2M | ﹤0.01% | 2003 |
|
|
2015
Q4 | $1.66M | Buy |
+51,157
| New | +$1.51M | ﹤0.01% | 1752 |
|
|
2015
Q3 | – | Sell |
-135,389
| Closed | -$6.52M | – | 3017 |
|
|
2015
Q2 | $6.52M | Buy |
135,389
+44,232
| +49% | +$2.58M | 0.02% | 1034 |
|
|
2015
Q1 | $5.55M | Buy |
91,157
+1,040
| +1% | +$63.5K | 0.01% | 1120 |
|
|
2014
Q4 | $4.67M | Buy |
+90,117
| New | +$3.97M | 0.01% | 1157 |
|
Other funds holding PTCT
RI
JT
Guggenheim Capital's PTCT Position: Q2 2026 in Review
Guggenheim Capital increased its PTC Therapeutics (PTCT) stake by 24% in Q2 2026, buying an estimated $464K and bringing the position to 32,811 shares worth $2.68M. The position accounts for 0.02% of the portfolio, ranked #637.
Guggenheim Capital first reported a position in PTCT in Q4 2014 and has held it in 33 quarters since. The position peaked at $6.52M in Q2 2015. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.
- Guggenheim Capital held 32,811 shares of PTC Therapeutics worth $2.68M as of Q2 2026.
- Guggenheim Capital bought 6,432 PTC Therapeutics shares in Q2 2026, an estimated $464K.
- PTC Therapeutics made up 0.02% of Guggenheim Capital's portfolio in Q2 2026, its #637 holding.
- Guggenheim Capital first reported a position in PTC Therapeutics in Q4 2014 and has held it in 33 quarters since.
- Guggenheim Capital's PTC Therapeutics position peaked at $6.52M in Q2 2015.
- 382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.
Based on Guggenheim Capital's 13F filing for Q2 2026, filed 12 Aug 2026.